{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:42:55Z","timestamp":1790779375530,"version":"4.1.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00005","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T04:39:16Z","timestamp":1579840756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":116,"title":["Metabolic Symbiosis in Chemoresistance: Refocusing the Role of Aerobic Glycolysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Lisi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nrc.2016.82","article-title":"Metabolic control of epigenetics in cancer","volume":"16","author":"Kinnaird","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","article-title":"Targeting mitochondria metabolism for cancer therapy","volume":"11","author":"Weinberg","year":"2014","journal-title":"Nat Chem Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/mc.21863","article-title":"Metabolic symbiosis in cancer: refocusing the Warburg lens","volume":"52","author":"Nakajima","year":"2013","journal-title":"Mol Carcinog"},{"key":"B7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-07-2460","article-title":"Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells","volume":"68","author":"Fuchs","year":"2008","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrc3368","article-title":"Cancer stem cell definitions and terminology: the devil is in the details","volume":"12","author":"Valent","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.cmet.2017.10.013","article-title":"Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment","volume":"26","author":"Bosc","year":"2017","journal-title":"Cell Metabol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov"},{"key":"B12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.6026\/97320630014080","article-title":"Current opinions on chemoresistance: an overview","volume":"14","author":"Hasan","year":"2018","journal-title":"Bioinformation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv Pharm Bull."},{"key":"B14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1016\/j.biocel.2009.08.012","article-title":"Bioenergetics of lung tumors: alteration of mitochondrial biogenesis and respiratory capacity","volume":"41","author":"Bellance","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101076","DOI":"10.1016\/j.redox.2018.101076","article-title":"Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance","volume":"2018","author":"Hirpara","year":"2018","journal-title":"Redox Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.redox.2018.101073","article-title":"Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors","volume":"2018","author":"Lee","year":"2018","journal-title":"Redox Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11060-004-6404-6","article-title":"Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines","volume":"74","author":"Griguer","year":"2005","journal-title":"J Neuro Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bbrc.2018.06.092","article-title":"Lactic acid induces lactate transport and glycolysis\/OXPHOS interconversion in glioblastoma","volume":"503","author":"Duan","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1038\/srep04927","article-title":"Beyond Warburg effect \u2013 dual metabolic nature of cancer cells","volume":"4","author":"Xie","year":"2014","journal-title":"Sci Reports"},{"key":"B21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbabio.2010.10.012","article-title":"Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma?","volume":"1807","author":"Jose","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.celrep.2016.04.028","article-title":"Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy","volume":"15","author":"Pisarsky","year":"2016","journal-title":"Cell Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","article-title":"The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma","volume":"8","author":"Pavlides","year":"2009","journal-title":"Cell Cycle"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.celrep.2016.04.015","article-title":"Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients","volume":"15","author":"Jim\u00e9nez-Valerio","year":"2016","journal-title":"Cell Reports"},{"key":"B25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00018-018-2961-2","article-title":"Mitochondrial dynamics and metastasis","volume":"76","author":"Altieri","year":"2019","journal-title":"Cell Mol Life Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.bbabio.2017.01.012","article-title":"Mitochondria and cancer chemoresistance","volume":"1858","author":"Guerra","year":"2017","journal-title":"Biochim Biophys Acta."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.4155\/fmc.14.100","article-title":"Targeting mitochondrial function for the treatment of breast cancer","volume":"6","author":"Deus","year":"2014","journal-title":"Fut Med Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3892\/ijo.2018.4476","article-title":"ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells","volume":"53","author":"Xu","year":"2018","journal-title":"Int J Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell."},{"key":"B30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.freeradbiomed.2019.03.009","article-title":"Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1\u03b1 in NSCLC which can be overcome by OXPHOS inhibition","volume":"135","author":"Cruz-Berm\u00fadez","year":"2019","journal-title":"Free Rad Biol Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.metabol.2015.10.007","article-title":"Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment","volume":"65","author":"Barron","year":"2016","journal-title":"Metabolism"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7865","DOI":"10.2147\/OTT.S176818","article-title":"Inhibition of GLUT-1 expression and the PI3K\/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro","volume":"11","author":"Jiang","year":"2018","journal-title":"OncoTargets Therapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-3-319-42118-6-6","article-title":"Metabolic Features of Cancer Treatment Resistance","volume":"207","author":"Viale","year":"2016","journal-title":"Recent Results Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-006-0291-9","article-title":"Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia","volume":"59","author":"Cao","year":"2007","journal-title":"Cancer Chemother Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.7785\/tcrt.2012.500343","article-title":"Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin","volume":"12","author":"Wang","year":"2013","journal-title":"Technol Cancer Res Treat"},{"key":"B36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1593\/neo.10526","article-title":"Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression","volume":"12","author":"Le Calv\u00e9","year":"2010","journal-title":"Neoplasia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"12351","DOI":"10.1021\/acsami.7b18437","article-title":"Overcoming multidrug resistance through the GLUT1-mediated and enzyme-triggered mitochondrial targeting conjugate with redox-sensitive paclitaxel release","volume":"10","author":"Ma","year":"2018","journal-title":"ACS Appl Mater Interfaces."},{"key":"B38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ejmech.2017.08.029","article-title":"Development of GLUT4-selective antagonists for multiple myeloma therapy","volume":"139","author":"Wei","year":"2017","journal-title":"Eur J Med Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/1568026618666180523105234","article-title":"Targeting key transporters in tumor glycolysis as a novel anticancer strategy","volume":"18","author":"Shi","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1038\/s41388-018-0386-x","article-title":"PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer","volume":"37","author":"Yang","year":"2018","journal-title":"Oncogene"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/0008-5472.CAN-11-0127","article-title":"Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism","volume":"71","author":"Zhao","year":"2011","journal-title":"Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e27222","DOI":"10.1371\/journal.pone.0027222","article-title":"Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells","volume":"6","author":"Nakano","year":"2011","journal-title":"PLoS ONE"},{"key":"B43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10863-012-9417-4","article-title":"A translational study \u201ccase report\u201d on the small molecule \u201cenergy blocker\u201d 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside","volume":"44","author":"Ko","year":"2012","journal-title":"J Bioenerget Biomembranes."},{"key":"B44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbrc.2013.09.041","article-title":"INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells","volume":"440","author":"Min","year":"2013","journal-title":"Biochem Biophys Res Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3892\/ol.2016.4168","article-title":"PKM2 and cancer: The function of PKM2 beyond glycolysis","volume":"11","author":"Dong","year":"2016","journal-title":"Oncol Lett"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e152090","DOI":"10.1371\/journal.pone.0152090","article-title":"MiR-122 reverses the doxorubicin-resistance in hepatocellular carcinoma cells through regulating the tumor metabolism","volume":"11","author":"Pan","year":"2016","journal-title":"PLoS ONE"},{"key":"B48","doi-asserted-by":"publisher","first-page":"45983","DOI":"10.1038\/srep45983","article-title":"Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Reports"},{"key":"B49","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1158\/1535-7163.MCT-08-0882","article-title":"A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines","volume":"8","author":"Martinez-Balibrea","year":"2009","journal-title":"Mol Cancer Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.2174\/0929867321666140414101056","article-title":"HIF-1 signaling in drug resistance to chemotherapy","volume":"21","author":"Warfel","year":"2014","journal-title":"Curr Med Chem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/333683a0","article-title":"Crystal structure of enolase indicates that enolase and pyruvate kinase evolved from a common ancestor","volume":"333","author":"Lebioda","year":"1988","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10549-009-0492-0","article-title":"Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells","volume":"121","author":"Tu","year":"2010","journal-title":"Breast Cancer Res Treatment."},{"key":"B53","doi-asserted-by":"publisher","first-page":"47691","DOI":"10.18632\/oncotarget.17868","article-title":"Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer","volume":"8","author":"Qian","year":"2017","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1159\/000489196","article-title":"ENO2 promotes cell proliferation, glycolysis, and glucocorticoid-resistance in acute Lymphoblastic Leukemia","volume":"46","author":"Liu","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2006.04.023","article-title":"Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance","volume":"9","author":"Fantin","year":"2006","journal-title":"Cancer Cell."},{"key":"B56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1476-4598-9-33","article-title":"Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol","volume":"9","author":"Zhou","year":"2010","journal-title":"Mol Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3892\/mmr.2016.5290","article-title":"Overcoming cetuximab resistance in Ewing's sarcoma by inhibiting lactate dehydrogenase-A","volume":"14","author":"Fu","year":"2016","journal-title":"Mol Med Reports."},{"key":"B58","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3892\/mmr.2014.2726","article-title":"Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil","volume":"11","author":"Li","year":"2015","journal-title":"Mol Med Reports"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1186\/s12935-018-0533-z","article-title":"Targeting FBPase is an emerging novel approach for cancer therapy","volume":"18","author":"Liu","year":"2018","journal-title":"Cancer Cell Int."},{"key":"B60","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.3892\/mmr.2017.7665","article-title":"Fructose1,6bisphosphatase1 decrease may promote carcinogenesis and chemoresistance in cervical cancer","volume":"16","author":"Li","year":"2017","journal-title":"Mol Med Reports"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-16-3143","article-title":"Fructose-1,6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1-MAPK interaction","volume":"77","author":"Jin","year":"2017","journal-title":"Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1042\/BST20130041","article-title":"A growing role for mTOR in promoting anabolic metabolism","volume":"41","author":"Howell","year":"2013","journal-title":"Biochem Soc Trans"},{"key":"B63","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12967-018-1543-2","article-title":"Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1alpha-dependent glycolysis through inactivation of the PI3K\/Akt\/mTOR pathway","volume":"16","author":"Gong","year":"2018","journal-title":"J Transl Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0065-230X(09)02002-8","article-title":"PI3K\/PTEN signaling in angiogenesis and tumorigenesis","volume":"102","author":"Jiang","year":"2009","journal-title":"Adv Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00109-011-0726-6","article-title":"mTOR links oncogenic signaling to tumor cell metabolism","volume":"89","author":"Yecies","year":"2011","journal-title":"J Mol Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3892\/mmr.2017.6189","article-title":"Glycometabolic adaptation mediates the insensitivity of drug-resistant K562\/ADM leukaemia cells to adriamycin via the AKT-mTOR\/c-Myc signalling pathway","volume":"15","author":"Zhang","year":"2017","journal-title":"Mol Med Reports"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","article-title":"Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s10637-018-0578-9","article-title":"A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer","volume":"36","author":"Graham","year":"2018","journal-title":"Invest New Drugs"},{"key":"B70","doi-asserted-by":"publisher","first-page":"80943","DOI":"10.18632\/oncotarget.13115","article-title":"Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1alpha and sphingosine kinase 1","volume":"7","author":"Alshaker","year":"2016","journal-title":"Oncotarget"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00005\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T04:39:18Z","timestamp":1579840758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00005\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":70,"alternative-id":["10.3389\/fonc.2020.00005"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00005","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"article-number":"5"}}